• 1989
  • In order to secure funding for a start-up company based on family funds, the Changs sought collaboration with Genentech in 1989, sending data and samples of early anti-IgE antibody, but talks with Genentech were unsuccessful. (wikipedia.org)
  • nausea
  • The most common adverse effects noted for second-generation agents include drowsiness, fatigue, headache, nausea and dry mouth. (wikipedia.org)
  • treatment
  • Chang is a cofounder of Tanox, a biopharmaceutical company specialized in anti-IgE therapies for the treatment of allergic diseases. (wikipedia.org)
  • Originating from Chang's research, antibodies that target the IgE-mediated allergic pathway have proven effective in the treatment of various allergic diseases. (wikipedia.org)
  • allergy
  • Proxicromil was developed in the late 1970s as an oral analogue and a successor of anti-allergy drug Intal, whose patent protection period was to expire in 1982. (wikipedia.org)
  • various
  • Urushiol-induced contact dermatitis (also called Toxicodendron dermatitis and Rhus dermatitis) is the medical name given to allergic rashes produced by the oil urushiol, which is contained in various plants, most notably those of the Toxicodendron genus: the Chinese lacquer tree, poison ivy, poison oak, and poison sumac. (wikipedia.org)
  • Activity
  • Besides its anti-histaminic activity, it is also a functional leukotriene antagonist and a phosphodiesterase inhibitor. (wikipedia.org)
  • early
  • Pirquinozol (SQ-13,847) is a drug which was investigated as an antiallergen and antiasthmatic agent in the early 1980s but was never marketed. (wikipedia.org)
  • known
  • A few years later, legal disputes arose as the Changs discovered that Genentech launched its own anti-IgE program, developing what now became known as Omalizumab (Xolair). (wikipedia.org)